Lv4
670 积分 2025-07-27 加入
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
1天前
已完结
Prime Editing for p47 phox -Deficient Chronic Granulomatous Disease
3天前
已完结
Celiac Disease
3天前
已完结
Morpholylureas are a new class of potent and selective inhibitors of the type 5 17-β-hydroxysteroid dehydrogenase (AKR1C3)
4天前
已完结
Sight restored by turning back the epigenetic clock
6天前
已完结
Discovery of FLC-8 as the First Covalent FLT3 Inhibitor Targeting Cys807 for FLT3 Mutant Acute Myeloid Leukemia
6天前
已完结
GLP-1 Receptor Agonists
8天前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
18天前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
28天前
已完结
Gene Therapy to Treat Profound Hearing Loss
1个月前
已完结
皖公网安备34019202002308
